Etzer Darout
Stock Analyst at Guggenheim
(2.09)
# 2,745
Out of 4,827 analysts
110
Total ratings
34.94%
Success rate
-4.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERV Verve Therapeutics | Maintains: Buy | $18 → $24 | $5.16 | +365.12% | 2 | Apr 15, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $3.57 | +152.45% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $7.63 | +162.12% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $44.32 | +62.47% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $101.10 | +41.44% | 4 | Mar 11, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.56 | +92.31% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.39 | +43.88% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $39.84 | +0.40% | 3 | Dec 20, 2024 | |
| TRML Tourmaline Bio | Initiates: Outperform | $50 | $15.91 | +214.27% | 1 | Dec 6, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $35 | $10.94 | +220.07% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $33.63 | +63.54% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $5.24 | +1,103.44% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.41 | +1,814.89% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $75.43 | +77.65% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $10.74 | +216.57% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $21.55 | +122.74% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $113.11 | +6.10% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $38 | $32.53 | +16.82% | 3 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 → $26 | $3.31 | +686.69% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $4.26 | +486.85% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.66 | +201.20% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.62 | +1,134.57% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $43.34 | +109.97% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.17 | +412.82% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.96 | +273.49% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $72.09 | +13.75% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $3.94 | +382.23% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $273.55 | -37.85% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $44.92 | +20.21% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $44.12 | -13.87% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.30 | +3,900.00% | 1 | Mar 28, 2018 |
Verve Therapeutics
Apr 15, 2025
Maintains: Buy
Price Target: $18 → $24
Current: $5.16
Upside: +365.12%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.57
Upside: +152.45%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $7.63
Upside: +162.12%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $44.32
Upside: +62.47%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $101.10
Upside: +41.44%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.56
Upside: +92.31%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.39
Upside: +43.88%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $39.84
Upside: +0.40%
Tourmaline Bio
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $15.91
Upside: +214.27%
Nurix Therapeutics
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $10.94
Upside: +220.07%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $33.63
Upside: +63.54%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $5.24
Upside: +1,103.44%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.41
Upside: +1,814.89%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $75.43
Upside: +77.65%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $10.74
Upside: +216.57%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $21.55
Upside: +122.74%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $113.11
Upside: +6.10%
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $32.53
Upside: +16.82%
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $3.31
Upside: +686.69%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $4.26
Upside: +486.85%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.66
Upside: +201.20%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.62
Upside: +1,134.57%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $43.34
Upside: +109.97%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.17
Upside: +412.82%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.96
Upside: +273.49%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $72.09
Upside: +13.75%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $3.94
Upside: +382.23%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $273.55
Upside: -37.85%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $44.92
Upside: +20.21%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $44.12
Upside: -13.87%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.30
Upside: +3,900.00%